IMMIX BIOPHARMA DL-,0001 Aktie

Immix Biopharma shares fell about 11.6% intraday after it emerged that the CMO hired in March as “Dr. Richard Graydon” is in fact Ronald Fischer, a fugitive who was recently arrested. The incident raised questions about the company’s leadership due diligence and corporate governance, especially as Immix approaches the topline readout of the approval‑relevant NEXICART‑2 study. Elevated short interest of roughly 20% amplified selling volume and sped the decline. The company reported the immediate removal of the CMO in an 8‑K filing. » More on de.investing.com

Immix Biopharma reports a 95% clinical response rate for its CAR‑T therapy NXC‑201 in AL amyloidosis. A $150 million capital raise in May 2026 secures funding for the research‑intensive company well into 2027. With the proceeds, Immix can independently advance the next steps toward market approval. » More on finanzen.net

Immix Biopharma completed a registered, underwritten offering of 16,778,524 common shares at $8.94 per share and generated about $140.65 million in net proceeds after fees. Institutional biotech investors and funds participated; Morgan Stanley and BofA Securities acted as book‑running managers, with LifeSci Capital, Mizuho and Needham as co‑lead managers. The capital infusion strengthens the balance sheet (InvestingPro reports more cash than debt); the stock trades at $8.78 (market capitalization $459.61 million) and analyst price targets range from $14.80 to $22.78. Immix is developing, among other programs, the BCMA‑targeted CAR‑T therapy NXC-201 for AL amyloidosis, which has already received multiple regulatory accelerations from the FDA and EMA. » More on de.investing.com